Drug treatments for Alzheimer's disease: Shifting the burden of care

CNS Drugs

Volumn 11, Issue 5, 1999, Pages 363-372

  Max, Wendy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; DONEPEZIL; ESTROGEN; GALANTAMINE; GINKGO BILOBA EXTRACT; METRIFONATE; PROPENTOFYLLINE; RIVASTIGMINE; TACRINE;

AGING; ALZHEIMER DISEASE; ATAXIA; CAREGIVER; COGNITION; DOWN SYNDROME; DRUG EFFECT; GASTROINTESTINAL SYMPTOM; GENETIC RISK; HEAD INJURY; HEADACHE; HEALTH CARE COST; HUMAN; INSTITUTIONALIZATION; LIFE EXPECTANCY; LIVER TOXICITY; MYALGIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR;

EID: 0032931185     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199911050-00004     Document Type: Review

References (42)

1. 1. Cotton P. Constellation of risks and processes seen in search for Alzheimer's clues. JAMA 1994; 271 (2): 89-91
2. 2. Small GW. Tacrine for treating Alzheimer's disease [editorial]. JAMA 1992; 268: 2564-5
3. 3. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997; 278 (16): 1363-70
4. 4. Evans D. Descriptive epidemiology of Alzheimer's disease. In: Khachaturian ZS, Radebaugh TS, editors. Alzheimer's disease. Cause(s), diagnosis, treatment, and care. New York: CRC Press, 1996: 51-9
5. 5. Evans D. Estimated prevalence of Alzheimer's disease in the United States. Milbank Q 1990; 68: 267-89
6. 6. Ott A, Breteler MB, van Harskapin F, et al. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. BMJ 1995; 310: 970-3
7. 7. Fratiglioni L, Viitanan M, von Strauss E, et al. Very old women at highest risk of dementia and Alzheimer's disease: Incidence data from the Kungsholmen Project, Stockholm. Neurology 1997; 48: 132-8
8. 8. Hofman A, Rocca WA, Brayne C, et al. The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Int J Epidemiol 1991; 20: 736-48
9. 9. Odenheimer GL. Management of patients with Alzheimer's disease. Pharmacotherapy 1991; 11: 237-41
10. 10. Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: A quantitative integration of the literature. Acta Psychiatr Scand 1987; 76: 465-79
11. 11. Rovner B, Kafonek S, Filipp L, et al. Prevalence of mental illness in a community nursing home. Am J Psychiatry 1986; 143 (11): 1446-9
12. 12. Schelling TC. The life you save may be your own. In: Chase SB, editor. Problems in public expenditure analysis. Washington DC: Brookings Institution, 1968
13. 13. Dorman P. Markets and mortality: economics, dangerous work, and the value of human life. Great Britain: Cambridge University Press, 1966: 77
14. 14. Miller TR. The plausible range for the value of life? Red herrings among the mackerel. J Forensic Econ 1990; 3 (3): 17-39
15. 15. Max W, Webber PA, Fox PJ. Alzheimer's disease: the unpaid burden of caring. J Aging Health 1995; 7 (2): 179-99
16. 16. Max W. Economic analysis in health care. In: Harrington C, Estes C, editors. Health policy and nursing: crisis and reform in the U.S. health care delivery system. 2nd ed. Boston: Jones and Bartlett Publishers, 1997: 283-95
17. 17. Winblad B, Hill S, Beerman B, et al. Issues in the economic evaluation of treatment for dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997; 11 Suppl. 3: 39-45
18. 18. Max W. The economic impact of Alzheimer's disease. Neurology 1993; 43: S6-S10
19. 19. Rice DR, Fox PJ, Max W, et al. The economic burden of Alzheimer's disease care. Health Aff 1993; 12: 165-76
20. 20. Hu T, Huang L, Cartwright W. Evaluation of the costs of caring for the senile demented elderly: a pilot study. Gerontologist 1986; 26: 158-63
21. 21. Ostbye T, Crosse E. Net economic costs of dementia in Canada. Can Med Assoc J 1994; 151 (10): 1457-64
22. 22. Wimo A, Karlsson G, Sandman PO, et al. Cost of illness due to dementia in Sweden. Int J Geriatr Psychiatry 1997; 12 (8): 857-61
23. 23. Welch HG, Walsh JS, Larson EB. The cost of institutional care in Alzheimer's disease: nursing home and hospital use in a prospective cohort. J Am Geriatr Soc 1992; 40: 221-4
24. 24. Gray A, Fenn P. Alzheimer's disease: the burden of the illness in England. Health Trends 1993; 25 (1): 31-7
25. 25. Stommel M, Collins CE, Given BA. The costs of family contributions to the care of persons with dementia. Gerontologist 1994; 34 (2): 199-205
26. 26. Weinberger M, Gold DT, Divine GW, et al. Expenditures in caring for patients with dementia who live at home. Am J Public Health 1993; 83: 338-41
27. 27. Souctre EJ, Qing W, Vigoureux I, et al. Economic analysis of Alzheimer's disease in outpatients: impact of symptom severity. Int Psychogeriatr 1995; 7 (1): 115-22
28. 28. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 1994; 84: 1261-4
29. 29. Huang L, Cartwright W, Hu T. The economic cost of senile dementia in the United States, 1985. Public Health Rep 1988; 103: 3-7
30. 30. Shihabuddin L, Davis KL. Treatment of Alzheimer's disease. In: Khachaturian ZS, Radebaugh TS, editors. Alzheimer's disease: cause(s), diagnosis, treatment, and care. New York: CRC Press, 1996: 257-74
31. 31. Knapp MJ, Knopman DS, Solomon PR, et al. Tacrine Study Group. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271 (13): 985-91
32. 32. Watkins PG, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271: 992-8
33. 33. Sano M, Ernesto C, Thomas RF, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997; 336: 1216-22
34. 34. Moller HJ, Maurer I, Saletu B. Placebo-controlled trial of the xanthine derivative propentofylline in dementia. Pharmacopsychiatry 1994; 27 (4): 159-65
35. 35. Wolf-Klein GP. New Alzheimer's drug expands your options in symptom management. Geriatrics 1993; 48 (8): 26-36
36. 36. Knopman D, Schneider L, Davis K, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology 1996; 47: 166-77
37. 37. Max W. The cost of Alzheimer's disease: will drug treatment ease the burden? Pharmacoeconomics 1996; 9 (1): 5-10
38. 38. Mundell I. Is tacrine worth the price? Inpharma 1993; 910: 3-4
39. 39. Lubeck DP, Mazonson PD, Bowe T. Potential effect of tacrine on expenditures for Alzheimer's disease. Med Interface 1994; 7 (10): 130-8
40. 40. Henke CJ, Burchmore MJ. The economic impact of tacrine in the treatment of Alzheimer's disease. Clin Ther 1997; 19 (2): 330-45
41. 41. Wimo A, Karlsson G, Nordberg A, et al. Treatment of Alzheimer disease with tacrine: a cost-analysis model. Alzheimer Dis Assoc Dis 1997; 11 (4): 191-200
42. 42. Ernst RL, Hay JW, Fenn C, et al. Cognitive function and the costs of Alzheimer disease: an exploratory study. Arch Neurol 1997; 54: 687-93